Amgen (AMGN) Met Primary Endpoint in Phase 3 of Talimogene Laherparepve on Melanoma
Tweet Send to a Friend
Amgen (Nasdaq: AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
